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Abstract: Aside from primary pre-
vention, early detection remains
the most effective way to decrease
mortality associated with the ma-
jority of solid cancers. Previous
cancer screening models are largely
based on classification of at-risk
populations into three conceptual-
ly defined groups (normal, cancer
without symptoms, and cancer
with symptoms). Unfortunately,
this approach has achieved limited
successes in reducing cancer mor-
tality. With advances in molecular
biology and genomic technologies,
many candidate somatic genetic
and epigenetic ‘‘biomarkers’’ have
been identified as potential predic-
tors of cancer risk. However, none
have yet been validated as robust
predictors of progression to cancer
or shown to reduce cancer mortal-
ity. In this Perspective, we first
define the necessary and sufficient
conditions for precise prediction of
future cancer development and
early cancer detection within a
simple physical model framework.
We then evaluate cancer risk pre-
diction and early detection from a
dynamic clonal evolution point of
view, examining the implications of
dynamic clonal evolution of bio-
markers and the application of
clonal evolution for cancer risk
management in clinical practice.
Finally, we propose a framework
to guide future collaborative re-
search between mathematical
modelers and biomarker research-
ers to design studies to investigate
and model dynamic clonal evolu-
tion. This approach will allow opti-
mization of available resources for
cancer control and intervention
timing based on molecular bio-
markers in predicting cancer
among various risk subsets that
dynamically evolve over time.
Introduction
Detection of cancer at an early stage
could significantly reduce cancer mortality
and the overall burden of cancer [1–4].
The most common cancer risk model is
based on the classification of the popula-
tion into three groups: (1) normal without
cancer, (2) asymptomatic cancer (detect-
able and potentially curable), and (3)
symptomatic cancer, [5,6]. This model
has provided a foundation for clinical
approaches to cancer screening and early
detection that have largely been based on
tissue morphological features observed
microscopically or via imaging. Recent
advances in cancer biology and molecular
technology now provide new opportunities
to further refine cancer risk models for use
in the clinic.
Inherited susceptibility and environ-
mental exposures, including infectious
agents, can modulate cancer risk in an
individual over time, but dynamic inter-
actions between these factors and evolving
somatic genetic abnormalities that lead to
cancer are poorly understood. With prog-
ress in molecular biology and genetics, it is
widely believed that a panel of biomarkers
assessing DNA, RNA, proteins, and/or
metabolic processes can eliminate the
shortcomings of morphologic diagnosis
for early detection and cancer risk predic-
tion. In fact, advances in technology have
identified many molecular abnormalities
that develop during neoplastic progres-
sion, some of which are highly associated
with cancer [7–10]. Currently, there is a
quest to find the perfect cancer biomark-
er(s) that could be used to separate
‘‘cancer’’ from ‘‘non-cancer’’. Yet, thus
far, no molecular biomarkers that signifi-
cantly reduce cancer mortality with satis-
factory sensitivity and specificity have
become widely used in the clinic for early
diagnosis or cancer risk prediction in the
general population, although some genetic
tests have been adopted for individuals
with inherited susceptibilities to cancer
[11]. The limited success in identifying
robust biomarkers has been attributed to
inadequate study designs or complexity of
biospecimens [12,13], biased biospecimens
[14], and technologic [13,15] and compu-
tational limitations [16–18]. Although all
of these reasons contribute to the limited
success of cancer biomarker development
to some degree, a fundamental challenge
to be considered for biomarker develop-
ment is the dynamic, stochastic nature of
clonal evolution.
In this paper, we first define cancer
‘‘risk prediction’’ and ‘‘early cancer detec-
tion’’ using two very simple physical
systems. We then introduce the dynamic,
clonal evolutionary concept as it relates to
biomarkers in cancer development and
review the challenges associated with the
Citation: Li X, Blount PL, Vaughan TL, Reid BJ (2011) Application of Biomarkers in Cancer Risk Management:
Evaluation from Stochastic Clonal Evolutionary and Dynamic System Optimization Points of View. PLoS Comput
Biol 7(2): e1001087. doi:10.1371/journal.pcbi.1001087
Editor: Claus O. Wilke, University of Texas at Austin, United States of America
Published February 24, 2011
Copyright:  2011 Li et al. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: Supported by NIH P01 CA91955 and RC1 CA146973 grants. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the
responsibility of the authors and does not necessarily represent the official views of the National Cancer
Institute or the National Institutes of Health.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: xili@fhcrc.org
PLoS Computational Biology | www.ploscompbiol.org 1 February 2011 | Volume 7 | Issue 2 | e1001087use of molecular markers in a clinical
model. Finally, we present a general
theoretical framework for using imperfect
biomarkers for cancer risk stratification in
the clinic, using a dynamic systems
approach. The goal of this Perspective is
to inspire an integrated approach to
theoretical modeling and biomarker re-
search in cancer risk management by
incorporating a clonal dynamic point of
view.
Event Detection and Prediction
in Deterministic and Stochastic
Systems
In order to better illustrate the problems
associated with event prediction and early
detection, we will introduce two simple
physical systems as shown in Figures 1 and
2. For the purposes of this illustration, we
are interested in determining (1) when the
light bulb will turn on (event prediction) or
(2) whether the light bulb is already on
(event detection).
Event Prediction and Event
Detection in a Deterministic System
We first investigate the question of event
prediction in the deterministic system (for
any given time point or initial state, the
system will always produce the same
outcome) as illustrated in Figure 1. In this
system, all of the switches (S1, S2, S3, and
S39) have been precisely identified and
characterized and the timers in the system
(A, B, and U) are 100% accurate and
clearly observable. In this deterministic
model, the status of the light bulb can
always be predicted perfectly by simply
observing timers A, B, and U (see Figure 1
legend for details). Therefore, the neces-
sary and sufficient conditions for 100%
successful event prediction in this system
are (1) all of the switches in the system are
identified and characterized, and (2) the
timers reflect the exact time (sufficient
conditions) that has elapsed since any two
switches have connected and are observ-
able.
The question of whether the event has
already occurred (light bulb is on) and the
time elapsed after occurrence (event de-
tection) can be answered in Figure 1 by
simply observing cumulative timer C.
Alternatively, it could be determined by
observing the status of switch(es) S3, (S39).
Thus, the necessary and sufficient condi-
tions for event detection can be deter-
mined by simply observing the status of
the final switches or cumulative timer C.
Event Prediction and Event
Detection in a Stochastic System
A stochastic system that may not always
result in the same outcome for any given
time point or initial state is shown in
Figure 2. In this system, one cannot make
a prediction with 100% accuracy as to
when the light bulb will turn on due to the
stochastic nature of switches S2 and S3 (or
S39) and timers A, B, and U. In order to
make a reasonably good prediction as to
when the light bulb will turn on, one will
need to periodically recheck the status of
the switches.
The ‘‘switches’’ in Figures 1 and 2 may
be viewed as similar to the abnormalities
(e.g., DNA mutations/LOH/chromosome
copy gain/loss) that develop during neo-
plastic progression, and the timers as the
time that has elapsed between the genomic
alterations. The event of turning on the
light bulb may be intuitively analogous to
the development of cancer. However,
neither of these models addresses the
complexity of neoplastic progression.
Biological Complexity of
Molecular Markers for Early
Detection of Cancer and Cancer
Risk Prediction
Environmental factors, inherited genetic
susceptibility, and dynamic gene–gene and
gene–environmental interactions can gener-
ate new somatic genetic or epigenetic
alterations in human cells. Some altered
cells continue to divide with a low rate of
genetic or epigenetic alterations, largely
maintaining genomic integrity, whereas
others continue to develop new alterations,
generating new variants on which selection
can act. Several investigators have used
genetic and genomic data to develop models
of neoplastic progression. Nowell proposed
that a single cell gains a selective genetic
advantage over neighboring normal cells,
rendering it ‘‘neoplastic’’ [19]. Genomic
instability and stepwise selection of genetic
variants lead to clonal expansions of viable
Figure 1. A simple deterministic physical system for illustrating event prediction and detection. In this system, an on-off switch, S1, is
connected to a power supply and timer A. Timer A and B or U are each connected to a switch (S2, S3, or S39) that will automatically connect the wire
when the timers count down to 0. Switch S3 or S39 is connected to cumulative timer C, which counts cumulative time since S3 or S39 is switched on
and which is connected to a light bulb that is situated in a metal box (whether the bulb is on or off is not observable directly). Timers A, B (and U), and
C are set to their initial position at 40, 60 (and 80), and 0 seconds, respectively. Timer A starts to count down after S1 is set to the ‘‘on’’ position by
turning power on. Timer A will count down 40 seconds, which will trigger S2 to switch to on position, which then triggers timer B and U to start
counting down (pathway U is used to represent a possible alternative pathway). After timer B runs 60 seconds or U runs 80 seconds, it will set S3 (or
S39) to be connected, respectively, which will trigger timer C to count down and at the same time the light bulb will turn on. If one path (either B/S3
or U/S39) is blocked, then the other one could still function to turn the light bulb on. Event prediction can be made with 100% certainty by observing
timers A, U, or B before the light bulb turns on and event detection can be determined with equal accuracy by observing cumulative timer C after the
light bulb is turned on.
doi:10.1371/journal.pcbi.1001087.g001
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and underlies solid tumor progression while
most variant cells or clones do not evolve to
cancer. Later, Fearon and Vogelstein [20]
first proposed a sequence of key genetic
events during the evolution of a normal
colon cell to colon cancer. Barrett et al. [21]
reported the evolution of neoplastic lineages
in Barrett’s esophagus using spatial and
temporal data in individual patients, includ-
ing ordering of early key genetic events, as
well as tracing genetic lineages of viable
clones that produced a cancer and clones
that were not selected for progression to
cancer. Based on molecular data and
population cancer incidence data, a number
of stochastic and mathematical models have
been proposed to evaluate mechanisms of
initiation and development of cancer [22–
26]. In addition, a stochastic system dynam-
ic modeling approach was utilized to study
the mechanisms of cancer genesis and
progression by using combined data from
various molecular biology studies [27]. The
stochastic properties of selected and nonse-
lected chromosomal abnormalities in hyper-
dynamic evolution was further illustrated by
a cell population heterogeneity study in
which the highest level of non-clonal
chromosome aberrations was closely cou-
pled with the strongest tumorigenicity [28].
Many studies have shown that ad-
vanced epithelial malignancies have typi-
cally accumulated large numbers of geno-
mic abnormalities not found in normal
cells, including whole or segmental chro-
mosome copy number amplifications,
deletions, loss of heterozygosity, transloca-
tions, and point mutations [29–35]. Jones
et al. [10] used spatial data from individual
patients with colorectal cancers and re-
ported that times between benign, inva-
sive, and metastatic colon tumors can be
estimated by analysis of the mutations they
have in common and knowledge of the
time it takes for cell division. Although
these biological and genetic models pro-
vide significant insights for understanding
evolution of a normal cell to cancer, all of
them have stochastic characteristics (sim-
ilar to Figure 2), and none of them meet
the conditions required for perfect cancer
risk prediction. This is because the exact
steps and precise time elapsed between
each step cannot be predicted with 100%
accuracy in contrast to Figure 1. As a
consequence, in clinical practice we will
likely have imperfect biomarkers to iden-
tify high risk persons for targeted preven-
tion strategies (cancer risk prediction) and
those with early stage curable cancer for
treatment (combination of cancer risk
prediction and early detection). We next
propose a schematic model that could be
used for modeling cancer risk manage-
ment with consideration of stochastic
characteristics in the evolution of cancer
(Figure 3) and more accurate risk stratifi-
cation using current molecular measure-
ments, as illustrated in Figure 4.
Cancer Risk Prediction, Early
Detection and Management: A
Dynamic Systems Point of View
Modeling the System
Previous models [5,6,36,37] developed
for cancer screening and early detection
have been based on the definition of three
conceptual stages: normal, cancer without
symptoms, and cancer with symptoms.
The analysis of screening for early detec-
tion of cancer was carried out using
assumptions about the statistical distribu-
tions of transition from non-cancer to
cancer and sojourn time. The approach
of using three conceptual stages for
classification of populations for modeling
screening is reasonable. However, these
models can not be easily related to, or
characterized by, the complexity of clonal
evolution as reported by recent genomic
studies using high throughput sequencing
or high density arrays.
One obvious approach is to use molec-
ular or genomic biomarkers to stratify
populations into various risk groups where
each group has its own cancer risk
distribution rather than treating overall
cancer risk as a single distribution pattern
in a population. However, molecular
biomarkers are likely to be imperfect and
have stochastic characteristics (Figure 3),
and thus far, none of them meet the
conditions required for perfect cancer risk
prediction. In practice, one will be using
imperfect biomarkers for both risk predic-
tion and early detection. As shown in
Figure 4, biomarkers could be used to
stratify populations into different risk
groups [38–43]. Each risk group could
then be individually managed, with the
goal of reducing the overall cancer risk
over time, given a set of fixed resources or
time constraints.
Our framework for cancer risk manage-
ment considers the situation in which
members in lower risk groups could
progress to higher risk groups over time
or, alternatively, members in higher risk
groups could regress to a lower risk status.
Such dynamic risk status will need to be
periodically re-evaluated over time using
biomarkers. Patients with cancer will be
treated immediately, while a high risk
group could be provided with an inter-
Figure 2. A simple stochastic physical system for illustrating event prediction and detection. Figure 2 is similar to Figure 1 except that
switches S2 and S3 (or S39) have probabilities of P’1 and P’2 (P’3) being switched to dead ends that will never lead to a pathway that causes the light
bulb to turn on (pathway U is used to represent a possible alternative pathway). The timers (A, B, and U) are also of random nature. In this system, due
to random nature of S2 and S3 (or S39) and timers, one will never be able to determine with precise accuracy when the light bulb will turn on, or
whether it will turn on at all.
doi:10.1371/journal.pcbi.1001087.g002
PLoS Computational Biology | www.ploscompbiol.org 3 February 2011 | Volume 7 | Issue 2 | e1001087Figure 3. Neoplastic evolution, cancer risk prediction, and early cancer detection. (A), (B), and (C) represent evolutionary stages in dynamic
clonal progression to cancer. (A) Early stages of clonal evolution have fewer selected genomic alterations, and most individuals do not progress to
cancer. (B) A minority of individuals will evolve additional genomic alterations, but the majority of these will not progress to cancer. (C) A small subset
of patients will accelerate development of genomic alterations leading to selection of increasing abnormal clones and progression to cancer. These
events are stochastic and there are no biomarkers that perfectly distinguish (A), (B), and (C). In this evolutionary process, most clones may evolve in
directions that do not lead to cancer (dark gray circles), whereas some others retain great potential for future progression to cancer or development
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prevention, or monitored more closely for
early detection. The lower risk groups
could be subjected to much less intensive
monitoring. Therefore, early detection
and cancer risk management would com-
prehensively consider a dynamic system
over a period of time that includes (1) the
absolute risk for each risk group (cancer
incidence rates), which is characterized by
molecular biomarkers and estimated
through population studies, (2) a pre-
specified level of late stage cancer reduc-
tion, (3) resources available for cancer risk
reduction or management, (4) the quality
of an individual’s life (effects of false
positive or false negative diagnosis on
quality of life), and (5) competing mortality
due to other causes as shown in Figure 4.
There are many potential mathematical
approaches to quantify or model such a
dynamic system (Figure 4) for cancer risk
management. In this Perspective, we
suggest one possible method using dynam-
ic system optimization to deal with clonal
evolution for cancer risk management
using biomarkers (Text S1).
Discussion and Concluding
Remarks
The development of cancer is a com-
plex process characterized by stochastic
accumulation of mutations and dynamic
evolution of clones [10,31,44–46]. To
date, most biomarkers are not directly
related to evolutionary dynamics, but
instead focus on specific pathways. How-
ever, extrapolating information from path-
ways to evolutionary dynamics remains a
challenge [47]. Recently, genome-based
cell population heterogeneity rather than
commonly shared pathways have been
linked to tumorigenicity [28]. Whole
genome instability measurements are also
closely linked to stages of cancer progres-
sion [29]. This body of evidence indicates
that useful biomarkers can be developed
directly using longitudinal measurements
of genomic instability.
Development of biomarkers for cancer
risk management should consider these
stochastic and dynamic properties over
time in neoplastic evolution. Using bio-
markers for cancer risk management
involves multi-level systems from cells to
individuals to populations. Better ways of
modeling multi-level systems and compre-
hending innate uncertainties in these
systems are areas in which great benefits
could be achieved [48]. We propose a
dynamic system optimization approach to
deal with the practical limitations of earlier
three-stage models (Figure 4 and Text S1).
The goal of this Perspective is to link the
dynamic, stochastic elements of clonal
evolution in neoplastic tissues in patients
followed over time. This would be best
accomplished by collaborations between
mathematical modelers and laboratory
researchers in longitudinal experimental
design, modeling, and parameter estima-
Figure 4. Cancer risk stratification and dynamic risk management using molecular biomarkers. Clinical patients or the general
population could be stratified objectively using molecular biomarkers. A set of robust and validated biomarkers is expected to stratify the majorityo f
patients into either high or low risk groups, and assign fewer patients to the intermediate risk group. The cancer risks of each group could be
managed with consideration of individual risk, risk-benefit assessment, quality of life available resources, and dynamic progression characteristics of
each group to achieve overall optimized results.
doi:10.1371/journal.pcbi.1001087.g004
of resistance to interventions to prevent or treat cancer (white circles), depending on selective pressures. Only a minority of the evolving clones will
eventually acquire the capacity to become cancerous (red circles), and progression to cancer can occur by multiple possible pathways, also illustrated
in the figure. The initial cancer cells may continue to divide locally and produce future metastases (purple circles in red block). The gray bar
surrounded by dashed lines at the bottom of the figure illustrates the use of biomarkers in a clonal evolutionary system. Biomarkers with increasing
specificity and sensitivity would shrink the gray block from either side toward the small center red bar, at the conceptual transition between non-
cancer and cancer. A biomarker with perfect sensitivity and specificity would exactly correspond to the position of the red bar with perfect separation
of cancer and non-cancer. Thus far, no biomarkers satisfy the necessary and sufficient conditions for precise cancer risk prediction or early cancer
detection (as in Figure 1).
doi:10.1371/journal.pcbi.1001087.g003
PLoS Computational Biology | www.ploscompbiol.org 5 February 2011 | Volume 7 | Issue 2 | e1001087tion oriented to practical application for
cancer risk management.
There are fundamental differences be-
tween our concept and the commonly
used three-stage (normal, cancer without
symptoms, and cancer with symptoms)
model for cancer screening: (1) we evalu-
ate cancer risk prediction and early
detection from a dynamic clonal evolu-
tionary point of view and its implication
for cancer risk management in clinical
practice; (2) based on stochastic clonal
evolution, we propose a framework to
guide future biomarker research to more
accurately stratify patients into various risk
groups, where each risk group has a
different cancer risk distribution, thereby
permitting an adaptive cancer risk strate-
gy; and (3) we propose that mathematical
models be developed for cancer risk
management that can be expanded for
modeling specific cancer or management
aspects, allowing optimization of available
resources and intervention timing based
on particular biomarker sensitivity and
specificity in predicting cancer among
various risk groups that dynamically
evolve over time (Text S1). In addition,
points (2) and (3) above take into account
clonal dynamics in cancer development,
including both progression and regression
depending on dynamic selective condi-
tions. Models using biomarkers for cancer
risk management should allow optimiza-
tion of various specific and objective
functions dynamically, which is different
from the traditional medical decision tree
approach. Note that we addressed intrinsic
stochastic properties of clonal dynamics in
cancer development, as distinct from issues
such as noise due to measurement error in
biomarker studies.
In summary, effective prevention and
early diagnosis strategies are critical to
reducing the cancer burden. We analyzed
the biological basis for using biomarkers
for cancer risk prediction and early
detection. This analysis shows that if and
only if biological pathways for cancer
development are fully determined and
quantified as in Figure 1, can perfect
accuracy for cancer risk prediction and
early detection be achieved. With the
advances of molecular technology and
knowledge, biomarkers could reach a high
level of accuracy in cancer risk prediction
and early detection and could be used to
guide clinical monitoring and interven-
tions but likely will never be perfectly
accurate. We propose that evaluation of
biomarker effectiveness for cancer risk
prediction and early detection be conduct-
ed with consideration of cancer evolution-
ary dynamics and dynamic optimization
modeling for risk management.
Supporting Information
Text S1 A dynamic optimization ap-
proach for cancer risk management and
early detection. In S1, we present a
framework of mathematical modeling for
cancer risk management using biomarkers
with consideration of stochastic clonal
evolution in neoplastic progression.
Found at: doi:10.1371/journal.pcbi.
1001087.s001 (0.03 MB DOC)
Acknowledgments
We thank David S. Cowan for computer
graphic support.
References
1. Wingo PA, Ries LA, Rosenberg HM, Miller DS,
Edwards BK (1998) Cancer incidence and
mortality, 1973–1995: a report card for the U.S.
Cancer 82: 1197–1207.
2. Etzioni R, Urban N, Ramsey S, McIntosh M,
Schwartz S, et al. (2003) The Case for Early
Detection. Nature Reviews Cancer Volume 3:
1–10.
3. Jemal A, Clegg LX, Ward E, Ries LA, Wu X,
et al. (2004) Annual report to the nation on the
status of cancer, 1975–2001, with a special feature
regarding survival. Cancer 101: 3–27.
4. O’Connell JB, Maggard MA, Ko CY (2004)
Colon cancer survival rates with the new
American Joint Committee on Cancer sixth
edition staging. J Natl Cancer Inst 96:
1420–1425.
5. Zelen M (1993) Optimal scheduling of examina-
tions for the early detection of disease. Biometrika
80: 279–293.
6. Prorok PC (1976) The theory of periodic
screening I. Lead time and proportion detected.
Advances in applied probability 8: 127–143.
7. Croce CM (2008) Oncogenes and cancer.
N Engl J Med 358: 502–511.
8. Esteller M (2008) Epigenetics in cancer.
N Engl J Med 358: 1148–1159.
9. Hanahan D, Weinberg RA (2000) The hallmarks
of cancer. Cell 100: 57–70.
10. Jones S, Chen WD, Parmigiani G, Diehl F,
Beerenwinkel N, et al. (2008) Comparative lesion
sequencing provides insights into tumor evolu-
tion. Proc Natl Acad Sci U S A 105: 4283–4288.
11. Robson ME, Storm CD, Weitzel J, Wollins DS,
Offit K (2010) American Society of Clinical
Oncology policy statement update: genetic and
genomic testing for cancer susceptibility. J Clin
Oncol 28: 893–901.
12. Diamandis EP (2010) Cancer biomarkers: can we
turn recent failures into success? J Natl Cancer
Inst 102: 1462–1467.
13. Hanash SM, Pitteri SJ, Faca VM (2008) Mining
the plasma proteome for cancer biomarkers.
Nature 452: 571–579.
14. Ransohoff DF (2005) Bias as a threat to the
validity of cancer molecular-marker research. Nat
Rev Cancer 5: 142–149.
15. Gerges N, Rak J, Jabado N (2010) New
technologies for the detection of circulating
tumour cells. Br Med Bull 94: 49–64.
16. Dettling M, Buhlmann P (2003) Boosting for
tumor classification with gene expression data.
Bioinformatics 19: 1061–1069.
17. Handl J, Knowles J, Kell DB (2005) Computa-
tional cluster validation in post-genomic data
analysis. Bioinformatics 21: 3201–3212.
18. Natsoulis G, El Ghaoui L, Lanckriet GR,
Tolley AM, Leroy F, et al. (2005) Classification
of a large microarray data set: algorithm
comparison and analysis of drug signatures.
Genome Res 15: 724–736.
19. Nowell PC (1976) The clonal evolution of tumor
cell populations. Science 194: 23–28.
20. Fearon ER, Vogelstein B (1990) A genetic model
for colorectal tumorigenesis. Cell 61: 759–767.
21. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ,
Galipeau PC, et al. (1999) Evolution of neoplastic
cell lineages in Barrett oesophagus. Nat Gen 22:
106–109.
22. Frank S (2007) Dynamics of Cancer: Incidence,
Inheritance, and Evolution. Princeton: Princeton
University Press. 378 p.
23. Luebeck EG, Moolgavkar SH (2002) Multistage
carcinogenesis and the incidence of colorectal
cancer. Proc Natl Acad Sci U S A 99: 15095–
15100.
24. Nowak MA, Komarova NL, Sengupta A,
Jallepalli PV, Shih I-M, et al. (2002) The role of
chromosomal instability in tumor initiation. Pro-
ceedings of the National Academy of Sciences of
the United States of America 99: 16226–16231.
25. Tan WY (1991) Stochastic Models for Carcino-
genesis. New York: Marcel Dekker, Inc. 264 p.
26. Yakovlev AY, Tsodikov AD, Asselain B (1996)
Stochastic models of tumor latency and their
biostatistical applications. River Edge: World
Scientific Publishing Co. 269 p.
27. Ao P, Galas D, Hood L, Yin L, Zhu XM (2010)
Towards predictive stochastic dynamical model-
ing of cancer genesis and progression. Interdiscip
Sci 2: 140–144.
28. Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS,
et al. (2009) Genome based cell population
heterogeneity promotes tumorigenicity: the evo-
lutionary mechanism of cancer. J Cell Physiol
219: 288–300.
29. Li X, Galipeau PC, Sanchez CA, Blount PL,
Maley CC, et al. (2008) Single nucleotide
polymorphism-based genome-wide chromosome
copy change, loss of heterozygosity, and aneu-
ploidy in Barrett’s esophagus neoplastic progres-
sion. Cancer Prev Res (Phila Pa) 1: 413–423.
30. Wood LD, Parsons DW, Jones S, Lin J,
Sjoblom T, et al. (2007) The genomic landscapes
of human breast and colorectal cancers. Science
318: 1108–1113.
31. Greenman C, Stephens P, Smith R, Dalgliesh GL,
Hunter C, et al. (2007) Patterns of somatic
mutation in human cancer genomes. Nature
446: 153–158.
32. Weir BA, Woo MS, Getz G, Perner S, Ding L,
et al. (2007) Characterizing the cancer genome in
lung adenocarcinoma. Nature 450: 893–898.
33. Tanemura A, Terando AM, Sim MS, van
Hoesel AQ, de Maat MF, et al. (2009) CpG
island methylator phenotype predicts progression
of malignant melanoma. Clin Cancer Res 15:
1801–1807.
34. Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, et al. (2010) The landscape of
somatic copy-number alteration across human
cancers. Nature 463: 899–905.
35. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ,
et al. (2008) Core signaling pathways in human
pancreatic cancers revealed by global genomic
analyses. Science 321: 1801–1806.
36. Flehinger BJ, Kimmel M (1987) The natural
history of lung cancer in a periodically screened
population. Biometrics 43: 127–144.
37. Lee SJ, Zelen M (1998) Scheduling periodic
examinations for the early detection of disease:
PLoS Computational Biology | www.ploscompbiol.org 6 February 2011 | Volume 7 | Issue 2 | e1001087Applications to breast cancer. Journal of the
American Statistical Association 93: 1271–1281.
38. Chen HY, Yu SL, Chen CH, Chang GC,
Chen CY, et al. (2007) A five-gene signature
and clinical outcome in non-small-cell lung
cancer. N Engl J Med 356: 11–20.
39. Galipeau PC, Li X, Blount PL, Maley CC,
Sanchez CA, et al. (2007) NSAIDs modulate
CDKN2A, TP53, and DNA content risk for
future esophageal adenocarcinoma. PLoS Med 4:
e67. doi:10.1371/journal.pmed.0040067.
40. Lee JJ, Hong WK, Hittelman WN, Mao L,
Lotan R, et al. (2000) Predicting cancer develop-
ment in oral leukoplakia: ten years of translational
research. Clin Cancer Res 6: 1702–1710.
41. Reid BJ, Li X, Galipeau PC, Vaughan TL (2010)
Barrett’s oesophagus and oesophageal adenocar-
cinoma: time for a new synthesis. Nat Rev Cancer
10: 87–101.
42. Shedden K, Taylor JM, Enkemann SA, Tsao MS,
Yeatman TJ, et al. (2008) Gene expression-based
survival prediction in lung adenocarcinoma: a multi-
site, blinded validation study. Nat Med 14: 822–827.
43. van ’t Veer LJ, Dai H, van de Vijver MJ, He YD,
Hart AAM, et al. (2002) Gene expression
profiling predicts clinical outcome of breast
cancer. Nature 415: 530–535.
44. Heng HH, Stevens JB, Lawrenson L, Liu G,
Ye KJ, et al. (2008) Patterns of genome dynamics
and cancer evolution. Cell Oncol 30: 513–514.
45. Siegmunda KD, Marjorama P, Woob Y,
Tavare S, Shibatab D (2008) Inferring clonal
expansion and cancer stem cell dynamics from
DNA methylation patterns in colorectal cancers.
Proc Natl Acad Sci U S A 106: 4828–4833.
46. Heng HH (2008) The conflict between complex
systems and reductionism.JAMA300: 1580–1581.
47. Sawyers CL (2008) The cancer biomarker
problem. Nature 452: 548–552.
48. Cohen JE (2004) Mathematics is biology’s next
microscope, only better; biology is mathematics’
next physics, only better. PLoS Biol 2: e439.
doi:10.1371/journal.pbio.0020439.
PLoS Computational Biology | www.ploscompbiol.org 7 February 2011 | Volume 7 | Issue 2 | e1001087